Featured:
Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19
12 April 2021
Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants. The drug is now available to treat COVID-19 on a case-by-case basis in UK primary care.
Latest research news and updates
Favipiravir to be investigated as a possible COVID-19 treatment for at-home recovery in the PRINCIPLE trial
8 April 2021
Could the antiviral favipiravir help transform COVID-19 into an illness that can be successfully treated by general practitioners?
PRINCIPLE COVID-19 treatments trial widens to under 50s and adds colchicine
3 March 2021
From today, the UK’s national priority platform trial of COVID-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.
Azithromycin and doxycycline are not generally effective against COVID-19 in patients treated at home, shows PRINCIPLE trial
25 January 2021
Update from the Chief Investigators of the Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE), 25 January 2021
De Montford University Leicester students to support PRINCIPLE trial recruitment
20 January 2021
Students from De Montfort University Leicester (DMU) are the first in the country to help drive the PRINCIPLE clinical study to find Covid-19 treatments for the over 50’s that can help speed up recovery.
Inhaled corticosteroids to be investigated as a possible treatment for Covid-19 in national PRINCIPLE Trial
27 November 2020
Inhaled budesonide is an inexpensive, safe and commonly prescribed treatment for asthma and COPD. It is the fourth medication to be tested in PRINCIPLE.
Two major pharmacy chains join PRINCIPLE Trial
18 November 2020
Two of the UK’s largest pharmacy chains, LloydsPharmacy and Well Pharmacy, are tasking their branches with helping to find suitable patients for the PRINCIPLE Trial of Covid-19 treatments.
Britain’s most influential Hindu temple spreads awareness of the PRINCIPLE trial among Indian community
21 October 2020
Europe’s BAPS Swaminarayan Sanstha, the largest Hindu temple outside of India, is supporting their community during the coronavirus pandemic by spreading awareness of the PRINCIPLE trial of Covid-19 treatments.
PRINCIPLE Trial of COVID-19 treatments recruits 1000th participant
1 October 2020
More than 1000 people across the UK have signed-up to take part in the UK-wide PRINCIPLE Trial of potential community-based treatments for COVID-19, led by Oxford University.
PRINCIPLE Trial to strengthen Black, Asian and minority ethnic community participation
18 September 2020
Professor Mahendra G Patel, University of Bradford, joins PRINCIPLE Trial as National Black, Asian and minority ethnic Community and Pharmacy Lead
PRINCIPLE and ZOE partner to widen access to trial
3 August 2020
Oxford University and the COVID Symptom Study app are joining forces to widen access to the PRINCIPLE trial of potential treatments for COVID-19.
PRINCIPLE Trial calls on UK primary care to support patient recruitment
22 June 2020
The Co-Chief Investigators of the PRINCIPLE Trial, Professor Chris Butler and Professor Richard Hobbs, write an open letter to health professionals across UK primary care calling on their support, so those who are still contracting COVID-19 are given the opportunity to join the trial.
National priority COVID-19 trial recruits first patients
17 April 2020
Researchers from Oxford University are now enrolling participants into PRINCIPLE, the first clinical trial of potential COVID-19 treatments to take place in GP practices.
GP practices urged to join COVID-19 research
30 March 2020
The Nuffield Department of Primary Care Health Sciences at the University of Oxford and the Royal College of General Practitioners (RCGP) have joined forces with clinical system supplier EMIS Health to urgently recruit as many GP practices as possible for COVID-19 research.